A dual-action HIV antibody–drug conjugate forces Env to open, then blocks it, boosting virus neutralization up to tenfold in the lab.

The chemokine receptors CCR5 and CXCR4 are the two major coreceptors for HIV entry. Numerous efforts have been made to develop a new class of anti-HIV agents that target these coreceptors as an ...

HOUSTON, Texas (KTRK) -- The Food and Drug Administration is currently reviewing a first-of-its-kind, twice-yearly injectable medication that experts say could revolutionize HIV prevention. The drug, ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

In 1987, four years after the discovery of HIV as the causative agent of AIDS, scientists reported the first drug effective against the virus, called zidovudine. Zidovudine targeted a viral enzyme ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

There's no vaccine for HIV, the virus that can lead to AIDS. And stories about people being cured of HIV are still read as miracles. HIV can, however, be prevented, controlled and treated with tablets ...

Brown researchers will look into how a drug originally developed to treat HIV may reduce age-related inflammation.

Independent clinical validation strengthens ABL’s leadership in the fast‑growing HIV drug‑resistance testing market ABL ...

Coinfection of HIV and HCV leads to worse outcomes, necessitating effective HCV treatment in this population. Direct-acting antivirals show over 95% efficacy, yet HCV clearance rates in coinfected ...

HIV is surging among adults over 50 in sub-Saharan Africa, yet prevention and treatment campaigns still focus mainly on the young. New research reveals older adults face comparable or higher infection ...